Sudeep Pharma, Since it was established in 1989, has broaded its operations from manufacturing excipients to offering a diverse of range of over 100 products with the pharmacical Sector, as of December 31, 2024. The company’s business is organized into two main segments: pharmaceutical, food and nutrition, and specialty ingredients.
The company has three manufacturing facilities located in vadodara, Gujarat, which togeether boast an annual production capacity of 65,579 mt. It employees a workforce of 37 individuals for various processes including encapsulation, spray drying, granulation, trituration, liposomal preparations, and blending.
As of December 31, 2024, The Company has catered to more than 1,100 customers and have established long-term partnerships with notable clients such as pfizer incine, intas pharmaceutials Limited, Mankindi Pharmai Limited, MERCK Group, Alembic Pharmaceutical Limited, Aurobindo Pharma Limited, Cadila Pharmaceutical Limited, IMCD Asia PTE. Ltd., Micro Labs Limited, and Danone Sa
For the nine-month period concluding on December 31, 2024, The Revenue from Operations and Profit after tax was 344.45 Crore and 94.54 Crore, respectively.
IPO Details
The Initial Public Offering (IPO), with a Nominal Value of Re 1 per Share, Includes a Fresh Isuance of 95 Crore AlongSide an offer for Sale of Up to 1,00,76,492 Equity Shares from the Promoter Selling Sharelder.
The offer for Sale Comprises Up to 35,67,670 Equity Shares from Sujit Jaysukh Bhayani, up to 5004622 Equity Shares from Sujeet Jaysukh Bhayani Huf, Up to 7,50,000 Equity Shares for Shares Shares Shares for Shares Sujit Bhayani, and up to 7,54,200 equity shares from Avani Sujit Bhayani.
After Discussions with the Book-Running Lead Managers, The Company May Opt for an issue of specified seconds totaling 19 Crore as a pre-soon, which shall not exced 20% of the fresh issue size. If such a placement occurs, the size of the fresh issue will be reduced.
The offer will be conducted via a book-building process, where no more than 50% of the offer will be allocated proportional Bidders, and a minimum of 35% will be set aside for retail individual bidders.
The funds generated from the fresh issue, Amouning to 75.81 Crore, will be used for capital expenses to Acquire machine for its production line at the nandesari facility I, as well as for general corporate needs.
ICICI Securities Limited and IIFL Capital Services Limited Serve as the Book-Running Lead Manners, What MUFG INTIME INTIME INTIME India Private Limited is designed as the registrar of The equity shares will be listed on both the bse and nse.
Disclaimer: The views and recommendations made about individual analysts or broking companies, and not of Mint. We Advise Investors to Check With Certified Experts Before Making Any Investments Decisions.